765 A Phase I Study of an IL-4-HSV-tk Gene-modified Autologous Glioma Vaccine: Technical Challenges and Promising Initial Results

Authors:

Abstract
INTRODUCTION: Patients with recurrent malignant gliomas have a poor prognosis with a median progression-free survival of less than 3 months. The use of novel, immunotherapeutically based strategies represents an appealing approach for such patients, provided issues of safety and efficacy can be confirmed.